Zacks Research Upgrades OPKO Health (NASDAQ:OPK) to Strong-Buy

OPKO Health (NASDAQ:OPK) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

A number of other research analysts have also weighed in on OPK. HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $1.55.

OPKO Health Price Performance

OPK opened at $1.62 on Monday. The company has a fifty day moving average price of $1.48 and a two-hundred day moving average price of $1.35. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35. The firm has a market capitalization of $1.21 billion, a PE ratio of -18.00 and a beta of 1.50. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.75.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. The business had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.19) earnings per share. As a group, analysts anticipate that OPKO Health will post -0.23 earnings per share for the current year.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. BlackRock Inc. bought a new stake in shares of OPKO Health in the second quarter worth $55,468,000. AWM Investment Company Inc. bought a new position in shares of OPKO Health in the 2nd quarter worth about $3,165,000. Bank of New York Mellon Corp acquired a new position in OPKO Health in the second quarter valued at approximately $1,995,000. OP Asset Management Ltd bought a new position in OPKO Health during the first quarter worth $1,257,000. Finally, Bank of America Corp DE acquired a new stake in shares of OPKO Health in the 2nd quarter valued at about $1,194,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Its diagnostics business includes BioReference Laboratories, which provides clinical laboratory testing and specialty diagnostic services in the United States, and the 4Kscore test, a blood-based test designed to help assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical activities include products and development programs in areas such as endocrinology, nephrology, and other specialty-care markets.